JP2005523718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523718A5 JP2005523718A5 JP2004501545A JP2004501545A JP2005523718A5 JP 2005523718 A5 JP2005523718 A5 JP 2005523718A5 JP 2004501545 A JP2004501545 A JP 2004501545A JP 2004501545 A JP2004501545 A JP 2004501545A JP 2005523718 A5 JP2005523718 A5 JP 2005523718A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- copy
- isolated polynucleotide
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 33
- 150000007523 nucleic acids Chemical class 0.000 claims 24
- 108091033319 polynucleotide Proteins 0.000 claims 21
- 102000040430 polynucleotide Human genes 0.000 claims 21
- 239000002157 polynucleotide Substances 0.000 claims 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 239000003623 enhancer Substances 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 206010021143 Hypoxia Diseases 0.000 claims 9
- 230000033115 angiogenesis Effects 0.000 claims 8
- 210000002889 endothelial cell Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 230000007954 hypoxia Effects 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 6
- 108010081589 Becaplermin Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 108020003519 protein disulfide isomerase Proteins 0.000 claims 5
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 210000003038 endothelium Anatomy 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 230000001146 hypoxic effect Effects 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/135,447 US7067649B2 (en) | 2000-11-17 | 2002-05-01 | Promoters exhibiting endothelial cell specificity and methods of using same |
| PCT/IL2003/000347 WO2003093409A2 (en) | 2002-05-01 | 2003-04-30 | Promoters exhibiting endothelial cell specificity and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523718A JP2005523718A (ja) | 2005-08-11 |
| JP2005523718A5 true JP2005523718A5 (enExample) | 2006-05-25 |
Family
ID=29399218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501545A Pending JP2005523718A (ja) | 2002-05-01 | 2003-04-30 | 内皮細胞特異性を示すプロモーター及びその使用法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7067649B2 (enExample) |
| EP (1) | EP1527084A4 (enExample) |
| JP (1) | JP2005523718A (enExample) |
| KR (1) | KR20040104685A (enExample) |
| CN (1) | CN1703420A (enExample) |
| CA (1) | CA2483996A1 (enExample) |
| MX (1) | MXPA04010711A (enExample) |
| WO (1) | WO2003093409A2 (enExample) |
| ZA (1) | ZA200408989B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20100282634A1 (en) * | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CA2463816C (en) * | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| AU2011205076B2 (en) * | 2004-11-14 | 2012-03-15 | Vascular Biogenics Ltd. | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US20060148695A1 (en) * | 2005-01-03 | 2006-07-06 | National Cheng Kung University | Novel angiogenic composition and use thereof |
| US20070161031A1 (en) * | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
| CA2658972C (en) | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| EP2135080A4 (en) * | 2007-03-08 | 2010-12-01 | Switchgear Genomics | FUNCTIONAL NETWORKS FOR THE CHARACTERIZATION OF TREATMENT OF REGULATORY ELEMENTS IN NON-TRANSLATED REGIONS OF GENES |
| WO2009045370A2 (en) | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
| CA2786377C (en) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera |
| DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| DK2908865T3 (en) | 2012-10-17 | 2019-01-28 | Vascular Biogenics Ltd | ADENOVIRUS THAT EXPRESSES A PHAS-CHIMARY AND ITS APPLICATION IN CANCER TREATMENT METHODS |
| WO2014123749A1 (en) | 2013-01-30 | 2014-08-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating complications associated with diabetes |
| EP2951307B1 (en) | 2013-02-04 | 2019-12-25 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| EP4059523A4 (en) * | 2019-11-15 | 2024-01-03 | Osaka University | Enhancer polynucleotide responding to heart failure and expression vector including said enhancer polynucleotide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747340A (en) * | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| EP1100941A2 (en) * | 1998-07-27 | 2001-05-23 | Valentis Inc. | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| IL155940A0 (en) * | 2000-11-17 | 2003-12-23 | Vascular Biogenics Ltd | Promoters exhibiting endothelial cell specificity and method of using same |
-
2002
- 2002-05-01 US US10/135,447 patent/US7067649B2/en not_active Expired - Lifetime
-
2003
- 2003-04-30 WO PCT/IL2003/000347 patent/WO2003093409A2/en not_active Ceased
- 2003-04-30 EP EP03717516A patent/EP1527084A4/en not_active Withdrawn
- 2003-04-30 JP JP2004501545A patent/JP2005523718A/ja active Pending
- 2003-04-30 CA CA002483996A patent/CA2483996A1/en not_active Abandoned
- 2003-04-30 KR KR10-2004-7017592A patent/KR20040104685A/ko not_active Ceased
- 2003-04-30 MX MXPA04010711A patent/MXPA04010711A/es not_active Application Discontinuation
- 2003-04-30 CN CNA038152622A patent/CN1703420A/zh active Pending
-
2004
- 2004-11-05 ZA ZA200408989A patent/ZA200408989B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523718A5 (enExample) | ||
| US6573092B1 (en) | Method of preparing a eukaryotic viral vector | |
| Li et al. | Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences | |
| Addison et al. | Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors | |
| Sandig et al. | Optimization of the helper-dependent adenovirus system for production and potency in vivo | |
| Szybalski et al. | Transcriptional units and their controls in Escherichia coli phage λ: operons and scriptons | |
| US20090298909A1 (en) | Multiple RNA Polymerase III Promoter Expression Constructs | |
| US20050101018A1 (en) | Viral vector encoding pigment epithelium-derived factor | |
| JP2010525805A5 (enExample) | ||
| JP2006115849A5 (enExample) | ||
| Hentsch et al. | The weak, fine-tuned binding of ubiquitous transcription factors to the II-2 enhancer contributes to its T cell-restricted activity | |
| JP2006500917A5 (enExample) | ||
| JP2003528604A5 (enExample) | ||
| Lusky et al. | Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3 | |
| Jacobs et al. | Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases | |
| JP2007522797A5 (enExample) | ||
| CN108840947A (zh) | 牛白蛋白-干扰素α-白介素2融合蛋白、制备方法及其编码基因、一种牛长效干扰素 | |
| Sowden et al. | Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription | |
| JP2004520009A5 (enExample) | ||
| JP4402457B2 (ja) | アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用 | |
| Stephenson | A CII-responsive promoter within the Q gene of bacteriophage lambda | |
| CN104513830B (zh) | 一种适用于氧化葡萄糖酸杆菌的基因表达载体及其应用 | |
| JPH11178A5 (enExample) | ||
| US7368553B2 (en) | Alternatively spliced nucleic acid molecules | |
| CN107253996A (zh) | 羊白蛋白‑干扰素τ‑白介素2融合蛋白、制备方法及其编码基因、一种羊长效干扰素 |